Fred Grossman, DO, FAPA, who serves as the head of Global Clinical Development and Medical Affairs at Sunovion Pharmaceuticals, discusses recent study results that indicated Aptiom (eslicarbazepine acetate), already approved as adjunct therapy for partial-onset seizures, may be effective as a monotherapy for patients with epilepsy.
With more than 2 million Americans affected by epilepsy, their course of treatment can affect not only how they handle the condition, but also their everyday quality of life. A recent study on an already approved medication may show more hope for the future.
At the 67th American Academy of Neurology Annual Meeting in Washington DC, results were presented for Aptiom as a monotherapy for epilepsy. Already approved as an adjunct therapy for partial-onset seizures, the results showed that equal or higher doses of the drug could provide enough of a benefit to be used on its own.
Fred Grossman, DO, FAPA, who serves as the head of Global Clinical Development and Medical Affairs at Sunovion Pharmaceuticals, discussed what this could mean for patients both in terms of their treatment options as well as the effect it could have on their wallets and peace of mind, as well